Cardio Diagnostics Inc.

Harnessing the Power of AI and Precision Epigenetics making heart disease prevention and early detection more accessible, personalized and precise.

[Cardio Diagnostics Inc. @PrecisionHeart]

Can summer weather impact your heart health? A study from @cwru and @UHhospitals found rising global temperatures could increase heat-related heart disease by 200 percent by 2050.

Understanding the link between heart health and the heat helps you recognize risks before a serious cardiac event takes place. Read our article to identify common heat risks, understand who’s most at risk, and learn how to keep your heart safe in the summer. https://t.co/IeDYeqGtnM

#HeartHealth #HeartDisease #HeatSafety #SummerHealth

[Cardio Diagnostics Inc. @PrecisionHeart]

Our team will be exhibiting at the Onsite Employee Health & Wellness Centers Conference in Chicago from June 25-26.  As healthcare costs escalate, onsite health facilities serve as a powerful strategy for employers to control costs while delivering quality care to employees. And employers are tapping into this trend: according to a joint study by the National Association for Workplace Health Care (NAWHC) and @AlliantIns, 54% of surveyed employers plan on expanding staff or services in their existing worksite health centers.

Our testing seamlessly integrates into existing clinic workflows without any upfront investment. This creates a win-win for employers and their employees, allowing clinics to expand their capabilities for patients without adding operational burden.

Meet with us at the conference to learn how we can implement our solutions into onsite health clinics to improve employee well-being and care.

#OnsiteCare #EmployeeHealth #EmployeeBenefits

[Cardio Diagnostics Inc. @PrecisionHeart]

We enjoyed meeting with union leaders at the Midwest Employee Benefit Funds Coalition Annual Meeting. The MEBFC serves approximately 350,000 members and their families with affordable and quality health care solutions.

Our CEO, Meesha Dogan, PhD, spoke with union leaders to discuss how we’re harnessing epigenetics and AI-powered precision cardiovascular medicine technology to reshape the future of heart health.

We partner with funds to set up a workflow that suits members and their families. Our clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™, can be implemented via telemedicine or onsite clinics and sample collected through at-home kits, onsite clinics, or heart health fairs. The result? A tailored cardiovascular risk assessment solution that meets the diverse needs of members and their loved ones.

#UnionHealthcare #UnionBenefits #HealthcareInnovation #MEBFC

[Cardio Diagnostics Inc. @PrecisionHeart]

Is stress silently affecting your heart?

Chronic stress can do more than leave you feeling overwhelmed. According to @American_Heart, it may also contribute to inflammation, high blood pressure, and increased cardiovascular risk.

Our latest article breaks down the impact of stress on your heart health and strategies for managing stress to reduce cardiovascular risk.

Read our full article here: https://t.co/VXDtJurIm4

#HeartHealth #StressManagement #PrecisionMedicine #PreventiveCare

[Cardio Diagnostics Inc. @PrecisionHeart]

Heart disease is the leading cause of death for men in the U.S. For many, the first warning can come too late.

Men face higher baseline risks when it comes to heart disease, including earlier risk of heart attack, silent high blood pressure, visceral fat, and vascular warning signs that are often ignored.

Read our article to learn more about male-specific risk factors and preventive actions to take. https://t.co/dXcM3OIOUH

#MensHealthWeek #HeartHealth #MensHealthAwareness #PreventiveCardiology #PrecisionMedicine

[Cardio Diagnostics Inc. @PrecisionHeart]

Our team had a great time in Philadelphia this past week at the #GPBCH Annual Conference and the #CSB Health & Benefits Innovation Summit!

We enjoyed the opportunity to make meaningful connections with benefit professionals and industry peers about how we’re using #AI, #Epigenetics, and #Genetics to drive innovation in cardiovascular medicine.

With our clinical blood tests, Epi+Gen CHD™ and PrecisionCHD™, individuals have greater visibility into their heart health, and through our population cardiovascular risk intelligence platform, HeartRisk™, benefit teams can better evaluate and monitor cardiovascular risk across their organization. Our solutions can reveal what traditional methods may miss, supporting healthier workforces and optimizing plan costs.

[Cardio Diagnostics Inc. @PrecisionHeart]

We believe heart health testing should be as simple and accessible as possible. No fasting is required, and our tests are non-invasive, requiring only a simple blood draw with no radiation involved.

Once ordered, a blood collection kit can be shipped directly to the patient’s home with everything needed to collect and ship their sample, so testing can be completed comfortably from home without a traditional in-person office visit. Learn more about how our at-home testing works here: https://t.co/e5WgOXzYF9

[Cardio Diagnostics Inc. @PrecisionHeart]

We’re looking forward to connecting with union leaders at the Midwest Employee Benefit Funds Coalition’s (MEBFC) Annual Meeting on June 12th. The MEBFC is committed to negotiating affordable health care solutions for their members, reaching approximately 350,000 employees, dependents, and retirees.

Healthcare is undergoing a serious cost crisis. Unions play a critical role in alleviating this challenge, while also ensuring its members and their families receive access to high-quality, tailored health benefits.

1 in every 5 heart attacks are silent, meaning recognizing the traditional signals aren’t enough (CDC). Our precision medicine solutions supply union members with deeper insight into their cardiovascular risk profile to help prevent a costly and life-altering cardiac event from taking place.

Join us at the event and learn how our advancements in cardiovascular risk detection and management can serve union members and their families.

#UnionHealthcare #UnionBenefits #HealthTech #MEBFC

[Cardio Diagnostics Inc. @PrecisionHeart]

We’re looking forward to attending the @connerstrong Health & Benefits Innovation Summit on Tuesday, June 9, at Citizens Bank Park. As health costs continue to surge, employee benefit professionals and union funds need innovative solutions that reduce overall healthcare spend while improving health outcomes across their covered populations.

At Cardio Diagnostics, we’re advancing next-generation cardiovascular testing solutions. By bridging AI, epigenetics, and genetics, we can detect cardiovascular risk earlier, facilitating targeted prevention strategies and reduced healthcare claims.

Meet with us at the event to learn about how our precision medicine solutions can support in managing high-cost claims and improving overall population health.

#HealthInsurance #EmployeeBenefits #HealthTech #CSB

[Cardio Diagnostics Inc. @PrecisionHeart]

In cardiovascular care, traditional tools can leave gaps. Conventional risk assessments often rely on proxy markers like cholesterol and blood pressure, while other tools are typically used to evaluate an individual once their disease status is more established. The problem is that coronary heart disease can begin developing earlier, more subtly, and through complex biological processes that may not be fully captured by conventional testing alone.

That gap can create false reassurance.

At Cardio Diagnostics, we believe cardiovascular care should go beyond one-size-fits-all testing. Our AI-driven approach integrates epigenetics and genetics to help deliver more precise insight across the care continuum, from risk stratification to disease detection and management.

Learn more about our cardiovascular care solutions here: https://t.co/OFVzeHP1MG

#HeartHealth #CoronaryHeartDisease #PrecisionMedicine #Epigenetics #AIinHealthcare

[Cardio Diagnostics Inc. @PrecisionHeart]

Cardiovascular disease remains a leading driver of employer medical spend, yet benefits teams don’t always have clear visibility to see it coming. Cardio Diagnostics is pioneering a new generation of cardiovascular medicine — built on AI, epigenetics, and genetics — that helps employers gain visibility into cardiovascular risk trends across their organization.

Interested in learning more? Connect with us at the Greater Philadelphia Business Coalition on Health Annual Conference, “The Employer Advantage: The Keys to Unlocking Your Power,” on Thursday, June 4, to see how our solutions come to life and help employers reduce downstream costs, establish tailored care programs and improve employee health outcomes.

#GPBCHAnnualConference #EmployeeHealth #WorkforceWellness

[Cardio Diagnostics Inc. @PrecisionHeart]

Cardiovascular disease does not affect all patients equally, and it is not always recognized equally, either.

According to a 2026 report by @American_Heart, cardiovascular disease accounted for 915,973 deaths in the U.S. in 2023. But a deeper look into the statistics tells a more comprehensive story beyond the number: your geography, race, ethnicity, socioeconomic status, and other factors affect your cardiovascular risk.

Rural communities face higher rates of early death from heart disease and stroke (CDC). Low-income populations also face a higher risk of hypertension, a known cardiovascular risk factor (American Heart Association). These effects can be compounded further depending on an individual's race/ethnicity.

Improving outcomes starts with recognizing these patterns. At Cardio Diagnostics, we believe more personalized cardiovascular risk assessment and disease detection can help support earlier action and more equitable care across underrepresented populations.

Sources: American Heart Association; CDC

#HeartHealth #CardiovascularDisease #HealthEquity #PopulationHealth

[Cardio Diagnostics Inc. @PrecisionHeart]

Smoking is one of the clearest drivers of coronary heart disease, and its effects go far beyond what we may see clinically. Tobacco exposure can alter the biology associated with cardiovascular risk at the epigenetic level.

What makes that especially important is that those changes may not be fixed.

A 2023 study co-authored by Cardio Diagnostics CMO Robert Philibert and CEO Meesha Dogan, used PrecisionCHDTM to examine DNA methylation changes during smoking cessation therapy. After 90 days, 5 of the 6 markers measured by the test showed significant reversion.

That finding adds an important layer to the conversation around smoking and heart health: quitting smoking is not only about reducing future risk. It may also be associated with measurable changes in the biology linked to coronary heart disease.

This World No Tobacco Day feels worth remembering.

#WorldNoTobaccoDay #HeartHealth #SmokingCessation #Epigenetics #CoronaryHeartDisease #PrecisionMedicine

Link to study: https://t.co/CbmhuObp8s

[Cardio Diagnostics Inc. @PrecisionHeart]

A PrecisionCHD™ result is reported as a binary output: CHD signal detected or not detected. This indicates whether a patient’s epigenetic and genetic signals, together, suggest the presence of coronary heart disease at the molecular level

The ordering provider also receives an Actionable Clinical Intelligence™ report that associates the patient’s epigenetic markers to potential biological drivers of disease.

These drivers may include inflammation, cholesterol metabolism, glucose dysregulation, oxidative stress, smoking-related vascular injury, and endothelial dysfunction. This gives providers added context to help personalize prevention and management decisions.

Learn more, https://t.co/unqztv2KyX

[Cardio Diagnostics Inc. @PrecisionHeart]

Epigenetics is the science that reveals how lifestyle and environment shape your biology. In cardiovascular disease, genetics accounts for less than 20% of risk, while the rest is influenced by factors beyond inherited DNA code.

By capturing measurable biological changes over time, epigenetics can help reveal clues related to heart disease risk earlier.

Learn how epigenetics influences heart disease risk here, https://t.co/VzTkRQAfEf

#epigenetics #precisionmedicine #heartdisease #CHD

[Cardio Diagnostics Inc. @PrecisionHeart]

Hypertension doesn’t announce its arrival with obvious symptoms. While a person may feel fine, the cardiovascular system is often navigating a high-pressure environment that acts as a silent precursor to heart disease.

Chronic high blood pressure causes arterial wear and forces the heart to overexert. This strain eventually thickens and weakens the heart muscle, directly elevating the risk of heart failure and heart attack.

The scale of hypertension in the United States is a significant clinical challenge:
- Nearly 119 million U.S. adults (about 48%) have high blood pressure.
- Only 1 in 4 of those individuals have the condition under control.

This makes hypertension a leading modifiable driver of heart disease and stroke across the country.

For decades, traditional risk calculators have been the standard for predicting cardiovascular events. However, these tools often fail to capture the full picture; many individuals suffer cardiac events despite appearing "low risk" on paper.

Hypertension is a great example where precision medicine solutions can support early intervention of heart disease. By augmenting a simple blood pressure reading with a patient's unique genetic and epigenetic profile, we can identify and manage cardiovascular risk with greater sensitivity.

Learn more about this approach, https://t.co/OFVzeHPzCe

#WorldHypertensionDay #HeartHealth #HypertensionAwareness #PrecisionMedicine #HeartDisease

[Cardio Diagnostics Inc. @PrecisionHeart]

Yes. PrecisionCHD™ is designed to detect molecular signals of coronary heart disease in both obstructive and non-obstructive disease. That matters because not all patients with coronary heart disease present with significant blockages on imaging, yet disease may still be present.

This is especially relevant in Ischemia with No Obstructive Coronary Arteries (INOCA), which is more common in women and can be missed by traditional imaging. PrecisionCHD™ can add clarity when symptoms and imaging do not fully align.

Learn more, https://t.co/unqztv2KyX

#chd #heartdisease #epigenetics #INOCA

[Cardio Diagnostics Inc. @PrecisionHeart]

Population averages are useful for identifying broad trends, but they do not tell the full story of what is happening internally for an individual patient. Two people can look similar on paper, share traditional risk factors, or even fall into the same “average-risk” category, yet have very different underlying biology and very different trajectories toward disease.

Cardio Diagnostics’ solutions are built on the premise that cardiovascular prevention improves when risk and disease are understood earlier and at the individual level.

By combining genetics, epigenetics, and AI, Cardio Diagnostics is enabling earlier cardiovascular assessments that are more precise and actionable, so prevention can happen before disease becomes destiny.

[Cardio Diagnostics Inc. @PrecisionHeart]

INOCA (ischemia with no obstructive coronary arteries) is a reminder that ischemia and coronary heart disease can still be present even when an angiogram looks “normal.” Patients can still have real disease, real symptoms, and real risk even when significant plaque is not visible. INOCA matters because these patients are often under-recognized and under-treated, despite evidence that non-obstructive coronary disease is not benign and can still carry meaningful cardiovascular risk.

This is where a more precise view of disease biology matters. PrecisionCHD™ is designed to detect molecular signals associated with coronary heart disease, including presentations that may be missed by traditional imaging alone, helping support clearer insight for detection and management when the clinical picture is more complex.

Read more about this here, https://t.co/OHSe29zWij

[Cardio Diagnostics Inc. @PrecisionHeart]

Cardiovascular care is not a single moment of diagnosis or treatment. It is a continuum. One that begins with understanding risk, continues through earlier identification of disease, and supports more informed management over time.

Yet coronary heart disease often develops silently, and for many patients, the first sign is a major event like a heart attack. Traditional risk factors and symptom-based approaches can leave important gaps in care.

Cardio Diagnostics is working to help close those gaps with blood-based clinical solutions designed to support different points along that journey: Epi+Gen CHD™ for 3-year coronary heart disease event risk assessment, and PrecisionCHD™ for coronary heart disease detection and management.

Learn more, https://t.co/OFVzeHPzCe